Clinical trials · Pennsylvania
Prostate Cancer (Adenocarcinoma) clinical trials in Pennsylvania
We’re tracking 53 recruiting prostate cancer (adenocarcinoma) studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Hershey, PennsylvaniaAges 18–100 - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Allentown, PennsylvaniaAges 40–75 - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Erie, PennsylvaniaAges 18 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Lancaster, PennsylvaniaAges 18 years+ - NCT06613100RecruitingPhase 1
Xaluritamig before prostate surgery for high-risk prostate cancer
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Philadelphia, PennsylvaniaAges 18–130 - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Doylestown, PennsylvaniaAges 21 years+ - NCT03678025RecruitingPhase 3
Standard treatment for metastatic prostate cancer, with or without local treatment
This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.
Gettysburg, PennsylvaniaAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Chadds Ford, PennsylvaniaAges 18 years+ - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Carlisle, PennsylvaniaAges 18 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after abiraterone
This trial tests whether a drug called talazoparib, alone or combined with enzalutamide, can help people with a certain type of advanced prostate cancer that has stopped responding to abiraterone. It is for those who have a specific genetic change (HRR mutation) in their tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05001477Recruiting
Registry for men receiving TULSA-PRO prostate treatment
This is a study registry that collects information from men who are going to receive TULSA-PRO treatment. It helps researchers understand how the treatment is used and what outcomes people experience.
York, PennsylvaniaAges 18 years+ - NCT05422911RecruitingPhase 2
Abiraterone, enzalutamide, or apalutamide for early castration prostate cancer
This Phase 2 trial tests whether abiraterone, enzalutamide, or apalutamide can work better (or differently) in men with prostate cancer that is considered “castration-sensitive.” It compares these hormone-blocking treatments to find an approach that controls the cancer more effectively and safely.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Gettysburg, PennsylvaniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07219303Recruiting
Adaptive radiation therapy for intermediate- or high-risk prostate cancer
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07222436Recruiting
Blood test for high-risk prostate cancer
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Allentown, PennsylvaniaAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Philadelphia, PennsylvaniaAges 18–130 - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Bala-Cynwyd, PennsylvaniaAges 18 years+
Prostate Cancer (Adenocarcinoma) trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting prostate cancer (adenocarcinoma) studies listed above.
- Thomas Jefferson University Hospital · 7 studies
- Fox Chase Cancer Center · 5 studies
- UPMC Hillman Cancer Center · 5 studies
- Geisinger Medical Center · 4 studies
- Geisinger Medical Oncology-Lewisburg · 4 studies
- Geisinger Wyoming Valley/Henry Cancer Center · 4 studies
- UPMC Shadyside Hospital · 4 studies
- MidLantic Urology · 3 studies
What taking part in a prostate cancer (adenocarcinoma) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate Cancer (Adenocarcinoma) trials in other states
Common questions
- Are there prostate cancer (adenocarcinoma) clinical trials in Pennsylvania?
- Yes. We're currently tracking 53 recruiting prostate cancer (adenocarcinoma) studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer (adenocarcinoma) study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer (adenocarcinoma) studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.